Substitute form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/[redacted]9,787
				Filing Date	September 30, 2004
				First Named Inventor	O'Dowd et al.
				Group Art Unit	1653
(use as many sheets as necessary)				Examiner Name	TBA
Sheet	A1	of	A2	Attorney Docket Number	3477-110

U.S. PATENTS AND PATENT PUBLICATIONS					
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
		US-			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation
		Office	Number	Kind Code (if known)			
✓	1.		WO 97/48820		Aurora BioSciences Corp.	24 December 1997	
✓	2.		WO 99/05177		The Regents of the Univ. of California	4 February 1999	

OTHER NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
✓	3.	Bailey et al.; "Patent Status of the therapeutically important G-protein-coupled receptors", *Expert Opin. Ther. Patents* **11**: 1861-1887 (2001).	
✓	4.	Barak et al.; "A β-Arrestin/Green Fluorescent Protein Biosensor for Detecting G Protein-coupled Receptor Activation", *The Journal of Biological Chemistry* **272**: 44 27497-27500 (1997).	
✓	5.	Bertin et al.; "Cellular signaling by an agonist-activated receptor/$G_s\alpha$ fusion protein", *Proc. Natl. Acad. Sci.* **91**: 8827-8831 (1994).	
✓	6.	Chen et al.; "A functional angiotensin II receptor-GFP fusion protein: evidence fro agonist-dependent nuclear translocation", *Am J Physical Renal Physiol* **279**: F440-F448 (2000).	
✓	7.	Conway et al.; "Quantitative analysis of Agonist-dependent parathyroid hormone receptor trafficking in whole cells using a functional green fluorescent protein conjugate", *J of Celular Phyisiol* **189**: 341-355 (2001).	
✓	8.	Coward et al.; "Chimeric G proteins allow a high-throughput signaling assay of G_i-Coupled receptors" *Analytical Biochemistry* **270**: 242-248 (1999).	
✓	9.	George et al.; "Oligomerization of μ and δ-Opioid receptors", *J of Biological Chemistry* **275:34** 26128-26135 (2000).	
✓	10.	George et al.; "G-protein-coupled receptor oligomerization and its potential for drug discovery", *Nature* **1**: 808-820 (2002).	
✓	11.	Görlich et al.; "Nucleocytoplasmic transport", *Science* **271**: 1513-1518 (1996).	
✓	12.	Grötzinger; "Molecular mechanisms of cytokine receptor activation", *Biochimica et Biophysica Acta* **1592**: 215-223 (2002).	
✓	13.	Hailey et al.; "Fluorescence resonance energy transfer using color variants of green fluorescent protein", *Methods in Enzymology* **351**: 34-49 (2002).	
✓	14.	Hanahan et al.; "Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis", *Cell* **86**: 353-364 (1996).	
✓	15.	Howard et al.; "Orphan G-protein-coupled receptors and natural ligand discovery", *Trends in Pharmacological Sciences* **22**:3 132-140 (2001).	
✓	16.	Howell et al.; "Live-cell nucleocytoplasmic protein shuttle assay utilizing laser confocal microscopy and FRAP", *BioTechniques* **32**: 80-87 (2002).	
✓	17.	Jans et al.; "Nuclear targeting signal recognition: a key control point in nuclear transport?", *BioEssays* **22**: 532-544 (2000).	
✓	18.	Lee et al.; "Novel G-protein-coupled receptor genes expressed in the brain: continued discovery of important therapeutic targets", *Expert Opin. Ther. Targets* **6**: 2 185-202 (2002).	
✓	19.	Lee et al.; "Oligomerization of dopamine and serotonin receptors", *Neuropsychopharmacology* **23**: S32-S40 (2000).	
✓	20.	Lu et al.; "Angiotensin II-Induced nuclear targeting of the Angiotenin Type 1 (AT_1) receptor in brain neurons", *Endocrinology* **139**:1 365-375 (1998).	
✓	21.	Masson et al.; "Neurotransmitter transporters in the central nervous system", *Pharmacological Reviews* **51**:3 439-464 (1999).	

Examiner Signature		Date Considered	12/20/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute form 1449A/PTO				Comp[illegible] if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/509,787
				Filing Date	September 30, 2004
				First Named Inventor	O'Dowd et al.
				Group Art Unit	1653
(use as many sheets as necessary)				Examiner Name	TBA
Sheet	A2	of	A2	Attorney Docket Number	3477-110

	22.	Matz et al.; "Fluorescent proteins from nonbioluminescent anthozoa species", *Nature Biotechnology* **17**: 969-973 (1999).	
	23.	Nakae et al.; "Distinct and overlapping functions of insulin and IGF-I receptors", *Endocrine Reviews* **22**: 6 818-835 (2001).	
	24.	Nicholson et al.; "EGFR and cancer prognosis", *European Journal of Cancer* **37**: S9-S15 (2001).	
	25.	O'Dowd et al.; "Short Communication: Discovery of three novel G-protein-coupled receptor genes", *Genomics* **47**: 310-313 (1997).	
	26.	Prasher et al.; "Primary structure of the Aequorea Victoria green-fluorescent protein", *Gene* **111**: 229-233 (1992).	
	27.	Schlenstedt; "Protein import into the nucleus", *Fed. Of Europ. Biocehm. Soc.* **389**: 75-79 (1996).	
	28.	Shawver et al.; "Smart drugs: tyrosine kinase inhibitors in cancer therapy", *Cancer Cell* **1**: 117-123 (2002).	
	29.	Smith; "Screening for drug discovery: the leading question", *Nature* **418**: 452-459 (2002).	
	30.	Strickland et al.; "Diverse roles for the LDL receptor family", *Trends in Endocrinology & Metabolism* **13**: 2 (66-73).	
	31.	Watson et al.; "Nuclear localization of the type 1 parathyroid hormone/parathyroid hormone-related peptide receptor in MC3T3-E1 cells: association with serum0induced cell proliferation", *Bone* **26**:3 221-225 (2000).	
	32.	Weis; "Importins and exportins: how to get in and out of the nucleus", *TIBS* **23**: 185-189 (1998).	
	33.	White et al.; "Heterodimerization is required for the formation of a functional $GABA_B$ receptor" *Nature* **396**: 679-682 (1998).	

Examiner Signature		Date Considered	11/20/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/509,787
		Filing Date	September 30, 2004
		First Named Inventor	Brian F. O'DOWD et al.
(use as many sheets as necessary)		Group Art Unit	1653
		Examiner Name	TBA
Sheet	B1 of B1	Attorney Docket Number	3477-110

U.S. PATENTS AND PATENT PUBLICATIONS

Examiner Initials*	Cite No.	U.S. Patent Document Number	U.S. Patent Document Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

U.S. PATENT APPLICATIONS

Examiner Initials*	Cite No.	U.S. Serial No.	Name of Applicant of Cited Document	Date of Filing of Cited Document MM-DD-YYYY
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document Office	Foreign Patent Document Number	Foreign Patent Document Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation
	1	WO	02/14475	A2	The Trustees of Columbia University in the City of New York	02/21/2002	

OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T

Examiner Signature		Date Considered	11/20/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.